Presage Biosciences was founded in November, 2008 based on technology invented
in the laboratory of Dr. James Olson, a pediatric oncologist focused on brain
tumors. Frustrated by a lack of tools to identify pre-existing resistance
to oncology drugs in his patients, Dr. Olson’s team developed a strategy
to assess tumor responses to drug treatments empirically, before subjecting
patients to a treatment cycle, frequently with side effects. Presage is using
Dr. Olson’s invention to improve the lives of cancer patients though drug
Presage closed its initial funding in November, 2009.
Presage signed its first research agreement with a major pharmaceutical company in December, 2009 and has since established two more commercial partnerships.